Acute toxicity testing in the nonlethal dose range: a new approach.
A new modification of acute toxicity testing of chemicals in rats is presented. Instead of using death as the principal criterion of toxicity, it is based on a careful, standardized clinical assessment of toxic signs measured in the nonlethal dose range. Test compounds are administered to groups of rats at four dose levels, selected on the basis of pilot experiments. General indices of toxicity, i.e., body weight gain, food and water consumption, and body temperature, are recorded at regular intervals; activity in the home cage is monitored continuously with a newly developed passive infrared device; neurobehavioral dysfunctions are assessed repeatedly with a checklist; and routine hematology is done on the 4th day after administration of the test compounds. All measured signs of toxicity are scored in relation to the control groups so that the absolute magnitude of the score increases as a function of the deviation from the normal conditions of the animals. In order to take into consideration the course of intoxication and the rate of recovery, toxicity scores are added over the duration of the whole experiment. For each variable measured, the resulting total scores are converted into a relative point system, scaling from 0 to 10 points. These points are added to a single "total ToxScore" value for each dose group. A regression line is calculated for these total ToxScore points, and the dose giving 15 total ToxScore points is determined. Based on the results obtained with nine reference substances, a classification system is proposed that is comparable to that based on LD50 values. It is concluded that the proposed test procedure provides much more information on the signs of acute toxicity, the course of the intoxication, the slope of the dose-effect curve, and the rate of recovery than does the standard LD50 test. In addition, the degree of distress and suffering of the animals is reduced.
Tamborini
P
P
Institute of Toxicology, Swiss Federal Institute of Technology.
Sigg
H
H
Zbinden
G
G
D000083:Acetanilides / Q000008:administration & dosage / Q000633:toxicity; D000284:Administration, Oral; D000814:Aniline Compounds / Q000008:administration & dosage / Q000633:toxicity; D000818:Animals; D001151:Arsenic / Q000008:administration & dosage / Q000633:toxicity; D000077237:Arsenic Trioxide; D001152:Arsenicals; D002104:Cadmium / Q000008:administration & dosage / Q000633:toxicity; D019256:Cadmium Chloride; D004305:Dose-Response Relationship, Drug; D005260:Female; D008722:Methods; D010087:Oxides; D010269:Paraquat / Q000008:administration & dosage / Q000633:toxicity; D010662:Phenylmercuric Acetate / Q000008:administration & dosage / Q000633:toxicity; D011041:Poisoning / Q000401:mortality; D011748:Pyrogallol / Q000008:administration & dosage / Q000633:toxicity; D051381:Rats; D011919:Rats, Inbred Strains; D012980:Sodium Salicylate / Q000008:administration & dosage / Q000633:toxicity; D013793:Thallium / Q000008:administration & dosage / Q000633:toxicity; D014116:Toxicology
D000083:Acetanilides; D000814:Aniline Compounds; D001152:Arsenicals; D010087:Oxides; D002104:Cadmium; D011748:Pyrogallol; D013793:Thallium; D019256:Cadmium Chloride; D001151:Arsenic; D010662:Phenylmercuric Acetate; D010269:Paraquat; D000077237:Arsenic Trioxide; C023650:aniline; C013707:thallium sulfate; D012980:Sodium Salicylate